A method to produce sedation in critically ill patients

Annals of Pharmacotherapy

Volumn 30, Issue 11, 1996, Pages 1227-1231

  Watling, Sharon M ^a,b,c   Johnson, Melissa ^c   Yanos, John ^d  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; HALOPERIDOL; LORAZEPAM; MORPHINE; NARCOTIC AGENT; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PENTOBARBITAL; VECURONIUM;

ACUTE RESPIRATORY FAILURE; ADOLESCENT; ADULT; AGED; APNEA; ARTICLE; ARTIFICIAL VENTILATION; BREATHING RATE; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CRITICAL ILLNESS; DOSE RESPONSE; DRUG TOLERANCE; ENTERIC FEEDING; FEMALE; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SEDATION;

EID: 0029910023     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001102     Document Type: Article

References (29)

1. Hall JB, Wood LD. Management of the patient on a ventilator. In: Hall JB, Schmidt GA, Wood LD, eds. Principles of critical care. New York: McGraw-Hill, 1992:1617-33.
2. Shelly M, Mendel L, Park G. Failure of critically ill patients to metabolize midazolam. Anaesthesia 1987;42:619-26.
3. Shelly M, Sultan M, Bodenham A, Park G. Midazolam infusions in critically ill patients. Eur J Anaesth 1991;8:21-7.
4. Shafer A, Doze VA, White PF. Pharmacokinetic variability of midazoiam infusions in critically ill patients. Crit Care Med 1990;18:1039-41.
5. Carrasco G, Molina R, Costa J, Soler JM, Cabre L. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients: a cost-benefit analysis. Chest 1993;103:557-64.
6. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992;327:524-8.
7. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994;22:884-93.
8. Bennett S, McNeil M, Bland L, Arduino M, Villarino M, Perrotta D, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995;333:147-54.
9. Collier C, Kelly K. Propofol and convulsions - the evidence mounts. Anaesth Intensive Care 1991;19:573-5.
10. El-Ebiary M, Torres A, Ramirez J, Xaubet A, Rodriguez-Roisin R. Lipid deposition during the long-term infusion of propofol. Crit Care Med 1995;23:1928-30.
11. Langley MS, Heel RC. Propofol: a review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic. Drugs 1988;35:334-72.
12. Parke T, Stevens J, Rice A, Greenaway C, Bray R, Smith P, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613-6.
13. Strickland RA, Murray MJ. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med 1995;23:405-9.
14. Pohlman AS, Simpson KP, Hall J. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. Crit Care Med 1994;22:1241-7.
15. Hoey LL, Vance-Bryan K, Clarens DM, Wright DH, Konstantinides FN, Guay DRP. Lorazepam stability in parenteral solutions for continuous intravenous administration. Ann Pharmacother 1996;30:343-6.
16. Buck ML, Blumer JL. Opioids and other analgesics. Crit Care Clin 1991; 7:615-37.
17. Watling S, Yanos J, Lonberger E, Lee S. Continuous infusion oral lorazepam for patients in the ICU (letter). Chest 1994;107:1915.
18. Reisine T, Paternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of theraputics. 9th ed. New York: McGraw-Hill, 1996:533.
19. 14C-lorazepam. Clin Pharmacol Ther 1976; 20:329-41.
20. McMurray T, Collier P, Lyons S, Elliot P. Propofol sedation after open heart surgery. Anaesthesia 1990;45:322-6.
21. Grounds R, Lumley JLJ, Royston D, Morgan M. Propofol infusion for sedation in the intensive care unit: preliminary report. Br Med J 1987; 294:397-400.
22. Aitkenhead AR, Pepperman ML, Willatts SM, Coates PD, Park GR, Bodenham AR, et al. Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 1989;2:704-9.
23. Harris C, Grounds R, Murray A, Lumley J, Royston C, Morgan M. Propofol for long-term sedation in the intensive care unit. Anaesthesia 1990;45:366-72.
24. Kupfer Y, Namba T, Kaldawi E, Tessler S. Prolonged weakness after long-term infusion of vecuronium bromide. Ann Intern Med 1992;117: 484-6.
25. Byatt C, Lewis L, Dawling S, Cochrane G. Accumulation of midazolam after repeated dosage in patients receiving mechanical ventilation in an intensive care unit. Br Med J 1984;289:799-800.
26. Byme A, Yeoman P, Mace P. Accumulation of midazolam in patients receiving mechanical ventilation (letter). Br Med J 1984;289:1309.
27. Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981;6:89-105.
28. Greenblatt DJ, Ehrenberg BL, Genderman J, Scavone JM, Tai NT, Harmatz JS, et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther 1989; 250:134-40.
29. Greenblatt D, Comer W, Elliot H, Knowles R, Ruelius H. Clinical pharmacokinetics of lorazepam. J Clin Pharmacol 1977;17:490-4.